NCT04257604 is a clinical trial of Perampanel in Partial Seizures, sponsored by Eisai Limited.

Who is sponsoring NCT04257604?

NCT04257604 is sponsored by Eisai Limited.

What drugs are being tested in NCT04257604?

Interventions in NCT04257604: Perampanel.

What condition does NCT04257604 study?

NCT04257604 studies Partial Seizures.

Is NCT04257604 still recruiting?

NCT04257604 is currently completed. Last updated 6 February 2020.

Last reviewed 2020-02-06 · How we verify

NCT04257604

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Completed Last updated 6 February 2020

What this trial tests

trial testing Perampanel in Partial Seizures in 243 participants. Completed in 30 April 2019.

Timeline

3 January 2016

Primary endpoint
30 April 2019

30 April 2019

Quick facts

Lead sponsor	Eisai Limited
Status	Completed
Study type	OBSERVATIONAL
Enrollment	243
Start date	3 January 2016
Primary completion	30 April 2019
Estimated completion	30 April 2019

Drugs / interventions tested

Perampanel (PERAMPANEL) — full drug profile →

Conditions studied

Partial Seizures — all drugs for Partial Seizures →

Sponsor

Eisai Limited — full company profile →

Who can join

12 and older, any sex, with Partial Seizures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the present study will be to assess the effectiveness of add-on perampanel in participants with focal seizures in a real-life clinical setting.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Real-world use of adjunctive perampanel for focal-onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents (AMPA).
D'Aniello A, Giallonardo AT, Tinuper P, Mecarelli O, et al · · 2025 · cited 3× · PMID 40468531 · DOI 10.1002/epi4.70068
Efficacy and safety of perampanel as first adjunctive therapy in patients with focal-onset seizures or generalized tonic-clonic seizures in four post-marketing studies across regions.
Meletti S, Punia V, Dash A, Gentile AL, et al · · 2026 · cited 1× · PMID 41239949 · DOI 10.1002/epi4.70183
Effect of adjunctive perampanel on daytime sleepiness and quality of life in adults with focal-onset seizures: Post hoc analyses of the AMPA study.
Liguori C, Assenza G, Chiacchiaretta M, Patten A, et al · · 2026 · PMID 41724127 · DOI 10.1016/j.yebeh.2026.110962

Verify or expand the search:

Other trials of Perampanel

Trials testing the same drug.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT04309721 — Perampanel in Focal Status Epilepticus · Phase 3 · terminated
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed

Other Eisai Limited trials

Trials by the same sponsor.

NCT06043700 — A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology · active not recruiting
NCT05607537 — A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-1 · Phase 1 · completed
NCT04840927 — A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets · Phase 1 · withdrawn
NCT04493255 — A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants · Phase 1 · completed
NCT04252846 — A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04257604 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Limited
Last refreshed: 6 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04257604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing